7,163 Shares in IQVIA Holdings Inc. $IQV Purchased by Impax Asset Management Group plc

Impax Asset Management Group plc acquired a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the third quarter, HoldingsChannel.com reports. The fund acquired 7,163 shares of the medical research company’s stock, valued at approximately $1,926,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Compass Financial Management LLC boosted its stake in IQVIA by 31.9% in the 3rd quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock worth $42,000 after purchasing an additional 38 shares in the last quarter. North Dakota State Investment Board grew its position in IQVIA by 0.8% during the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock worth $1,361,000 after purchasing an additional 40 shares during the last quarter. Boston Trust Walden Corp increased its stake in IQVIA by 1.9% during the 3rd quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock valued at $712,000 after purchasing an additional 50 shares in the last quarter. Apella Capital LLC increased its stake in IQVIA by 4.7% during the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 55 shares in the last quarter. Finally, Brighton Jones LLC raised its holdings in shares of IQVIA by 0.7% in the third quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock worth $2,191,000 after buying an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on IQV shares. Evercore lifted their price objective on shares of IQVIA from $275.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. BMO Capital Markets boosted their price objective on shares of IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Royal Bank Of Canada upped their target price on IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Deutsche Bank reduced their target price on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Finally, TD Cowen raised their target price on IQVIA from $288.00 to $307.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.

Read Our Latest Research Report on IQV

Insider Activity

In other news, insider Eric Sherbet sold 4,446 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the transaction, the insider owned 24,989 shares of the company’s stock, valued at $6,967,682.87. The trade was a 15.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The SEC filing for this sale provides additional information. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.1%

NYSE:IQV opened at $257.97 on Thursday. The firm has a market capitalization of $42.51 billion, a P/E ratio of 31.35, a PEG ratio of 2.29 and a beta of 1.16. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50. The company’s fifty day moving average price is $267.49 and its 200-day moving average price is $212.26. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83.

IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm’s revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the company posted $3.00 earnings per share. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Further Reading

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.